Insulin-like growth factor binding protein-2 as a novel biomarker for disease activity and renal pathology changes in lupus nephritis

H. Ding, M. Kharboutli, R. Saxena, T. Wu

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Lupus nephritis (LN) is one of the most serious manifestations of systemic lupus erythematosus. Invasive renal biopsy remains the gold standard for the diagnosis and management of LN. The objective of this study is to validate serum insulin-like growth factor binding protein-2 (IGFBP-2) as a novel biomarker for clinical disease and renal pathology in LN. Eighty-five biopsy-proven lupus nephritis patients, 18 chronic kidney disease (CKD) patients and 20 healthy controls were recruited for enzyme-linked immunosorbent assay (ELISA) testing of serum IGFBP-2 levels. Compared to CKD patients of origins other than lupus or healthy controls, serum IGFBP-2 levels were elevated significantly in LN patients. Serum IGFBP-2 was able to discriminate LN patients from the other two groups of patients [area under the curve (AUC)=0·65, 95% confidence interval (CI)=0·52-0·78; P = 0·043 for LN versus CKD; 0·97, 95% CI=0·93-1·00; P <0·0001 for LN versus healthy controls]. Serum IGFBP-2 was a potential indicator of both global disease activity and renal disease activity in LN patients, correlated with serum creatinine levels (r=0·658, P

Original languageEnglish (US)
Pages (from-to)11-18
Number of pages8
JournalClinical and Experimental Immunology
Volume184
Issue number1
DOIs
StatePublished - Apr 1 2016

Fingerprint

Insulin-Like Growth Factor Binding Protein 2
Lupus Nephritis
Biomarkers
Pathology
Kidney
Serum
Chronic Renal Insufficiency
Confidence Intervals
Biopsy
Systemic Lupus Erythematosus
Area Under Curve
Creatinine
Enzyme-Linked Immunosorbent Assay

Keywords

  • Biomarkers
  • IGFBP2
  • Lupus nephritis
  • Pathology

ASJC Scopus subject areas

  • Immunology
  • Immunology and Allergy

Cite this

Insulin-like growth factor binding protein-2 as a novel biomarker for disease activity and renal pathology changes in lupus nephritis. / Ding, H.; Kharboutli, M.; Saxena, R.; Wu, T.

In: Clinical and Experimental Immunology, Vol. 184, No. 1, 01.04.2016, p. 11-18.

Research output: Contribution to journalArticle

@article{e9066fc875b44ac3a8f48b0a8afe0cab,
title = "Insulin-like growth factor binding protein-2 as a novel biomarker for disease activity and renal pathology changes in lupus nephritis",
abstract = "Lupus nephritis (LN) is one of the most serious manifestations of systemic lupus erythematosus. Invasive renal biopsy remains the gold standard for the diagnosis and management of LN. The objective of this study is to validate serum insulin-like growth factor binding protein-2 (IGFBP-2) as a novel biomarker for clinical disease and renal pathology in LN. Eighty-five biopsy-proven lupus nephritis patients, 18 chronic kidney disease (CKD) patients and 20 healthy controls were recruited for enzyme-linked immunosorbent assay (ELISA) testing of serum IGFBP-2 levels. Compared to CKD patients of origins other than lupus or healthy controls, serum IGFBP-2 levels were elevated significantly in LN patients. Serum IGFBP-2 was able to discriminate LN patients from the other two groups of patients [area under the curve (AUC)=0·65, 95{\%} confidence interval (CI)=0·52-0·78; P = 0·043 for LN versus CKD; 0·97, 95{\%} CI=0·93-1·00; P <0·0001 for LN versus healthy controls]. Serum IGFBP-2 was a potential indicator of both global disease activity and renal disease activity in LN patients, correlated with serum creatinine levels (r=0·658, P",
keywords = "Biomarkers, IGFBP2, Lupus nephritis, Pathology",
author = "H. Ding and M. Kharboutli and R. Saxena and T. Wu",
year = "2016",
month = "4",
day = "1",
doi = "10.1111/cei.12743",
language = "English (US)",
volume = "184",
pages = "11--18",
journal = "Clinical and Experimental Immunology",
issn = "0009-9104",
publisher = "Wiley-Blackwell",
number = "1",

}

TY - JOUR

T1 - Insulin-like growth factor binding protein-2 as a novel biomarker for disease activity and renal pathology changes in lupus nephritis

AU - Ding, H.

AU - Kharboutli, M.

AU - Saxena, R.

AU - Wu, T.

PY - 2016/4/1

Y1 - 2016/4/1

N2 - Lupus nephritis (LN) is one of the most serious manifestations of systemic lupus erythematosus. Invasive renal biopsy remains the gold standard for the diagnosis and management of LN. The objective of this study is to validate serum insulin-like growth factor binding protein-2 (IGFBP-2) as a novel biomarker for clinical disease and renal pathology in LN. Eighty-five biopsy-proven lupus nephritis patients, 18 chronic kidney disease (CKD) patients and 20 healthy controls were recruited for enzyme-linked immunosorbent assay (ELISA) testing of serum IGFBP-2 levels. Compared to CKD patients of origins other than lupus or healthy controls, serum IGFBP-2 levels were elevated significantly in LN patients. Serum IGFBP-2 was able to discriminate LN patients from the other two groups of patients [area under the curve (AUC)=0·65, 95% confidence interval (CI)=0·52-0·78; P = 0·043 for LN versus CKD; 0·97, 95% CI=0·93-1·00; P <0·0001 for LN versus healthy controls]. Serum IGFBP-2 was a potential indicator of both global disease activity and renal disease activity in LN patients, correlated with serum creatinine levels (r=0·658, P

AB - Lupus nephritis (LN) is one of the most serious manifestations of systemic lupus erythematosus. Invasive renal biopsy remains the gold standard for the diagnosis and management of LN. The objective of this study is to validate serum insulin-like growth factor binding protein-2 (IGFBP-2) as a novel biomarker for clinical disease and renal pathology in LN. Eighty-five biopsy-proven lupus nephritis patients, 18 chronic kidney disease (CKD) patients and 20 healthy controls were recruited for enzyme-linked immunosorbent assay (ELISA) testing of serum IGFBP-2 levels. Compared to CKD patients of origins other than lupus or healthy controls, serum IGFBP-2 levels were elevated significantly in LN patients. Serum IGFBP-2 was able to discriminate LN patients from the other two groups of patients [area under the curve (AUC)=0·65, 95% confidence interval (CI)=0·52-0·78; P = 0·043 for LN versus CKD; 0·97, 95% CI=0·93-1·00; P <0·0001 for LN versus healthy controls]. Serum IGFBP-2 was a potential indicator of both global disease activity and renal disease activity in LN patients, correlated with serum creatinine levels (r=0·658, P

KW - Biomarkers

KW - IGFBP2

KW - Lupus nephritis

KW - Pathology

UR - http://www.scopus.com/inward/record.url?scp=84960360230&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84960360230&partnerID=8YFLogxK

U2 - 10.1111/cei.12743

DO - 10.1111/cei.12743

M3 - Article

C2 - 26616478

AN - SCOPUS:84960360230

VL - 184

SP - 11

EP - 18

JO - Clinical and Experimental Immunology

JF - Clinical and Experimental Immunology

SN - 0009-9104

IS - 1

ER -